Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III

Trial Profile

Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Apr 2017

At a glance

  • Drugs Darapladib (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms AIM-III
  • Most Recent Events

    • 07 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record. (NCT01067339)
    • 22 Sep 2015 Planned End Date changed from 1 Apr 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.
    • 22 Sep 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top